Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Quickens Pace Of Polymers IPO, Other Non-Core Businesses Next?

This article was originally published in Scrip

Executive Summary

You may also be interested in...



Xarelto Is The Pharma Watchword In Bayer's 3Q Update

Despite Bayer AG's third quarter earnings call being heavily dominated by talk of the company's ongoing Monsanto acquisition and its recent deconsolidation of material science company Covestro, Xarelto stood out as the hot topic within the German firm's pharma division.

Pipeline Watch: Phase III Starts With EB-101, Tavapadon, Ziresovir

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Bayer's Efforts To Pioneer Tumor-Agnostic Market In Europe Held Back

Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.

 

Topics

Related Companies

UsernamePublicRestriction

Register

SC029676

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel